Poly(ADP-ribose) Glycohydrolase (PARG) Inhibitors: Mechanisms of Action, Structural Optimization, and Combination Therapeutic Strategies in Cancer Therapy

In recent years, poly(ADP-ribose) glycohydrolase (PARG), a key enzyme in DNA damage repair pathways, has emerged as a major focus in anticancer drug discovery. PARG inhibitors exhibit broad-spectrum antitumor effects across diverse tumor types via multiple mechanisms, such as triggering sustained nuclear replication stress and mitotic catastrophe, as well as modulating the stability of cell cycle checkpoint proteins. This review systematically summarizes the mechanisms of action of PARG inhibitors, recent advances in their structural optimization, and their applications in combination with immunotherapy, ATR/CHK1 inhibitors, and natural products, aiming to highlight the unique value and clinical translation prospects of PARG inhibitors as a new generation of highly selective, multi-mechanism antitumor agents.

Authors

Institutions

Publication Details

Journal
Pharmaceutics
Published
2026-11-20
DOI
https://doi.org/10.3390/pharmaceutics18111496
Primary Topic
PARP inhibition in cancer therapy
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Poly(ADP-ribose) Glycohydrolase (PARG) Inhibitors: Mechanisms of Action, Structural Optimization, and Combination Therapeutic Strategies in Cancer Therapy

Guangzhi Shan, Xiaodan Qiu, Kun Xiao, Biao Li et al.
3 links
Pharmaceutics
PARP inhibition in cancer therapy
article

Poly(ADP-ribose) Glycohydrolase (PARG) Inhibitors: Mechanisms of Action, Structural Optimization, and Combination Therapeutic Strategies in Cancer Therapy

Guangzhi Shan, Xiaodan Qiu, Kun Xiao, Biao Li, Limin Zuo, Zhiling Zhu, Yiran Li, Yechun Zhang
article en

Abstract

In recent years, poly(ADP-ribose) glycohydrolase (PARG), a key enzyme in DNA damage repair pathways, has emerged as a major focus in anticancer drug discovery. PARG inhibitors exhibit broad-spectrum antitumor effects across diverse tumor types via multiple mechanisms, such as triggering sustained nuclear replication stress and mitotic catastrophe, as well as modulating the stability of cell cycle checkpoint proteins. This review systematically summarizes the mechanisms of action of PARG inhibitors, recent advances in their structural optimization, and their applications in combination with immunotherapy, ATR/CHK1 inhibitors, and natural products, aiming to highlight the unique value and clinical translation prospects of PARG inhibitors as a new generation of highly selective, multi-mechanism antitumor agents.

PharmaceuticsVol. 18(11)
Chinese Academy of Medical Sciences & Peking Union Medical College (CN), Institute of Medicinal Plant Development (CN)
Chinese Academy of Medical Sciences Initiative for Innovative Medicine
Good health and well-being
PARP inhibition in cancer therapy
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon